Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6889005 | 0.83 | NPC1 (0.43) | LMNAMAPTKMT2ANPC1RAB9A | |
| SCHEMBL6883982 | 0.81 | MAPK1 (0.36) | LMNAMAPTCYP1A2MEN1KMT2A | |
| SCHEMBL7055336 | 0.74 | MAPT (0.43) | MAPTCYP1A2MEN1KMT2AALDH1A1 | |
| SCHEMBL7097302 | 0.74 | LMNA (0.36) | LMNAMAPTCYP1A2MEN1KMT2A | |
| SCHEMBL4034128 | 0.73 | HCAR2 (0.62) | MAPTMEN1KMT2ANPC1RAB9A | |
| SCHEMBL444734 | 0.73 | MAPT (0.42) | LMNAMAPTCYP1A2MEN1KMT2A | |
| SCHEMBL7053837 | 0.73 | MAPT (0.42) | MAPTCYP1A2MEN1KMT2AALDH1A1 | |
| SCHEMBL1536321 | 0.72 | CHRNA4 (0.52) | MAPTCYP1A2MEN1KMT2AALDH1A1 | |
| SCHEMBL16935060 | 0.72 | MAPT (0.41) | LMNAMAPTRAB9AALDH1A1KDM4E | |
| SCHEMBL7048303 | 0.72 | MAPT (0.41) | MAPTCYP1A2MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6835842-B2 | Microbiocides; bactericides | BAYER AKTIENGESELLSCHAFT (DE) | 2004-12-28 | — | — | US | claimed |
| US-20030207929-A1 | 3-nitroisoxazoles and their use in the protection of materials | LANXESS DEUTSCHLAND GMBH (DE) | 2003-11-06 | — | — | US | claimed |
| US-20030166698-A1 | 3-NITROISOXAZOLES AND THEIR USE IN THE PROTECTION OF MATERIALS | LANXESS DEUTSCHLAND GMBH (DE) | 2003-09-04 | — | — | US | claimed |
| US-6835842-B2 | Microbiocides; bactericides | BAYER AKTIENGESELLSCHAFT (DE) | 2004-12-28 | — | — | US | disclosed |
| US-20030207929-A1 | 3-nitroisoxazoles and their use in the protection of materials | LANXESS DEUTSCHLAND GMBH (DE) | 2003-11-06 | — | — | US | disclosed |
| US-6638958-B2 | 3-nitroisoxazoles and their use in the protection of materials | BAYER AKTIENGESELLSCHAFT (DE) | 2003-10-28 | — | — | US | disclosed |
| US-20030166698-A1 | 3-NITROISOXAZOLES AND THEIR USE IN THE PROTECTION OF MATERIALS | LANXESS DEUTSCHLAND GMBH (DE) | 2003-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166698-A1 | 3-NITROISOXAZOLES AND THEIR USE IN THE PROTECTION OF MATERIALS | GPX1, NOX1, XDH | LMNA 1036/4885MAPT 4089/4885CYP1A2 43/4885 |
| US-20030207929-A1 | 3-nitroisoxazoles and their use in the protection of materials | GPX1, NOX1, XDH | LMNA 1036/4885MAPT 4089/4885CYP1A2 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.